Taken together, these results suggest that Y20 may have a great therapeutic potential in the treatment of obesity-induced cardiac injury using Nrf2 and NF-κB as the therapeutic targets for treating obesity-related disorders. Here, NFE2L2 is linked to obesity due to melanocortin 4 receptor deficiency.